CD Capital is a dynamic investment firm specializing in medical technology and life sciences, with a strategic focus on supporting innovative healthcare and biotechnology companies. The firm has built an impressive portfolio of over 90 investments, totaling more than $1.4 billion, demonstrating its commitment to advancing cutting-edge medical solutions and transformative health technologies.
The company’s investment strategy centers on identifying and nurturing promising startups and emerging companies across various medical domains, including genomics, diagnostics, medical robotics, digital health, and advanced medical technologies. Their portfolio showcases a diverse range of companies such as Berry Genomics, Urotronic, SprintRay Inc, and Surgerii Robotics, each representing different innovative approaches to addressing healthcare challenges and improving medical outcomes.
Led by founding partners like Ching Tan and seasoned professionals such as Larissa Lin and Tianji Zhu, CD Capital brings deep expertise and a strategic approach to venture investment in the healthcare sector. The firm’s guiding principles of “Focus, Excellence, Credibility” are reflected in their track record of supporting portfolio companies through critical growth stages, helping them achieve significant milestones like successful funding rounds, technological advancements, and even public listings on major stock exchanges.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
